The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Spain Edition: The Views of 154 Spanish Patient Groups

The ‘Corporate Reputation of Pharma’ survey - the 2021 Spain edition is now in its 8th year, and two years into the Covid-19 pandemic. Between November 2021-February 2022, the survey collected the opinions of 154 Spain-based patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups possess a unique understanding of the needs of the patients and represent their collated views. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct, as well as into the evaluation of clinical outcomes. At the same time, many patient groups are also familiar with the complexities of pharma’s business. From their vantage point, therefore, patient groups are both able to assess pharma, and recommend ways in which companies can improve - all from a patient perspective.

2021’s 154 respondent Spanish patient groups had, collectively, been in communication with nearly 850,000 Spanish patients during the year. 79% of the Spanish patient groups responding to the 2021 ‘Corporate Reputation of Pharma’ survey worked or partnered with at least one pharma company that year.

The report provides details on: 

• How the analyst measures pharma’s corporate reputation from a patient perspective; 
• The headline results of the 2021 Spain element of the ‘Corporate Reputation’ survey; 
• The companies included in the 2021 Spain analysis; and 
• The profiles of 2021’s respondent Spanish patient groups. 

Companies assessed for corporate reputation in the 2021 Spain report 

AbbVie - Almirall - AstraZeneca - Bayer - Biogen - Boehringer Ingelheim - Bristol Myers Squibb - Eli Lilly - Gilead Sciences - Grifols - GSK - Janssen - MSD - Novartis - Pfizer - Roche - Sandoz - Sanofi - Takeda - ViiV Healthcare  

COMPANY RANKINGS IN SPAIN IN 2021 

• The top-three pharma companies in Spain in 2021, out of 20 companies, ranked for their overall corporate reputation (as assessed by respondent Spanish patient groups familiar with the company): ViiV Healthcare, 1st - Janssen, 2nd - Gilead Sciences, 3rd.
• The top-three pharma companies in Spain in 2021, out of 12 companies, ranked for their overall corporate reputation (as assessed by respondent Spanish patient groups working with the company): Gilead Sciences, 1st - ViiV Healthcare, 2nd - Janssen, 3rd.
• The top-three ‘big-pharma’ companies in Spain in 2021, out of 12 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Spanish patient groups familiar with the company): Janssen, 1st - AbbVie, 2nd - Pfizer, 3rd.
• The top-three ‘big-pharma’ companies in Spain in 2021, out of 10 ‘big-pharma’ companies, ranked for their overall corporate reputation (as assessed by respondent Spanish patient groups working with the company): Janssen, 1st - AbbVie, 2nd - Novartis, 3rd.